Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Tremblay

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Journal of Comparative Effectiveness Research|March 18, 2021
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemiaGabriel Tremblay, Patrick Daniele, Timothy Bell, et al.
Plos One|March 6, 2019
Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinomaGabriel Tremblay, Heather J McElroy, Tracy Westley, et al.
Cost Effectiveness and Resource Allocation : C/E|December 13, 2019
Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patientsYogesh Suresh Punekar, Na Guo, Gabriel Tremblay, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Cancer Management and Research|May 17, 2018
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Anna Forsythe, David Chandiwana, Janina Barth, et al.
Journal of Comparative Effectiveness Research|March 15, 2018
Number needed to treat in indirect treatment comparisonPatricia Guyot, Wei Cheng, Gabriel Tremblay, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 9, 2018
Systematic review of health state utility values for acute myeloid leukemiaAnna Forsythe, Patricia S Brandt, Mike Dolph, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 24, 2020
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in FranceGabriel Tremblay, Clemence Cariou, Christian Recher, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 10, 2019
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United StatesGabriel Tremblay, Qayyim Said, Anuja Nidumolu Roy, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 1, 2019
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisonsGabriel Tremblay, Tracy Westley, Joseph C Cappelleri, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Journal of Comparative Effectiveness Research|March 18, 2021
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemiaGabriel Tremblay, Patrick Daniele, Timothy Bell, et al.
Plos One|March 6, 2019
Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinomaGabriel Tremblay, Heather J McElroy, Tracy Westley, et al.
Cost Effectiveness and Resource Allocation : C/E|December 13, 2019
Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patientsYogesh Suresh Punekar, Na Guo, Gabriel Tremblay, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Cancer Management and Research|May 17, 2018
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Anna Forsythe, David Chandiwana, Janina Barth, et al.
Journal of Comparative Effectiveness Research|March 15, 2018
Number needed to treat in indirect treatment comparisonPatricia Guyot, Wei Cheng, Gabriel Tremblay, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 9, 2018
Systematic review of health state utility values for acute myeloid leukemiaAnna Forsythe, Patricia S Brandt, Mike Dolph, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 24, 2020
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in FranceGabriel Tremblay, Clemence Cariou, Christian Recher, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 10, 2019
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United StatesGabriel Tremblay, Qayyim Said, Anuja Nidumolu Roy, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 1, 2019
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisonsGabriel Tremblay, Tracy Westley, Joseph C Cappelleri, et al.
Pageof 6